

Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial



Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, and Jun Guo

In the earlier version of this article as it was published online on July 21, 2020 (1) and in the printed article, the Results section contained incorrect progression-free survival values at 3.6 months. The values in the abstract were correct (95% confidence interval, 2.7–5.3). The HTML and PDF versions of this article were corrected in the online release of the August 15, 2020 issue (2). The authors regret the error.

References

1. Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. *Clin Cancer Res* 2020 Jul 21 [Epub ahead of print].
2. Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. *Clin Cancer Res* 2020;26:4250–9.

Published online September 15, 2020.
Clin Cancer Res 2020;26:5048
doi: 10.1158/1078-0432.CCR-20-3168
©2020 American Association for Cancer Research.

Clinical Cancer Research

Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Bixia Tang, Zhihong Chi, Yingbo Chen, et al.

Clin Cancer Res 2020;26:5048.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/18/5048>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/26/18/5048.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/26/18/5048>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.